Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Screeners that run automatically... and then email you the results! FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Entheon Biomedical Corp (ENBI.CN)

Entheon Biomedical Corp (ENBI.CN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 2,364
  • Shares Outstanding, K 59,089
  • Annual Sales, $ 22 K
  • Annual Income, $ -8,887 K
  • 60-Month Beta 1.94
  • Price/Sales 56.71
  • Price/Cash Flow N/A
  • Price/Book 0.38
Trade ENBI.CN with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.11
  • Most Recent Earnings -0.02 on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.040 unch
on 09/30/22
0.085 -52.94%
on 09/07/22
-0.030 (-42.86%)
since 08/26/22
3-Month
0.040 unch
on 09/30/22
0.100 -60.00%
on 08/11/22
-0.040 (-50.00%)
since 06/30/22
52-Week
0.040 unch
on 09/30/22
0.710 -94.37%
on 11/08/21
-0.225 (-84.91%)
since 09/30/21

Most Recent Stories

More News
Cybin (NYSE American: CYBN) (NEO: CYBN) Poised to Accelerate CYB004 Clinical Program

Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions, has completed the acquisition...

CYBN.NE : 0.670 (+4.69%)
CYBN : 0.4840 (+0.83%)
ENBI.CN : 0.040 (-11.11%)
ENTBF : 0.0340 (-10.53%)
Ketamine Ushering in New Era in the Pharmacology Therapies for Neurological Disorders

Palm Beach, FL – July 27, 2022 – For years, ketamine was known for its use as an anesthetic or as a recreational drug. Its ability to provide quick and safe sedation saved many lives during the Vietnam...

CYBN.NE : 0.670 (+4.69%)
SILO : 5.38 (+3.96%)
FTRP : 4.2105 (+1.07%)
FTRP.TO : 1.09 (+5.83%)
ATAI : 3.31 (+1.85%)
CYBN : 0.4840 (+0.83%)
ENBI.CN : 0.040 (-11.11%)
ENTBF : 0.0340 (-10.53%)
CMPS : 10.73 (-2.19%)
Cybin (NYSE American: CYBN) (NEO: CYBN) Acquires DMT Study

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that, through its wholly-owned subsidiary Cybin IRL Limited,...

CYBN.NE : 0.670 (+4.69%)
CYBN : 0.4840 (+0.83%)
ENBI.CN : 0.040 (-11.11%)
ENTBF : 0.0340 (-10.53%)
Cybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical

Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announced that, through...

CYBN.NE : 0.670 (+4.69%)
CYBN : 0.4840 (+0.83%)
ENBI.CN : 0.040 (-11.11%)
ENTBF : 0.0340 (-10.53%)
Cybin Acquires DMT Clinical Study from Entheon Biomedical

Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announced that, through its wholly-owned...

CYBN.NE : 0.670 (+4.69%)
CYBN : 0.4840 (+0.83%)
ENBI.CN : 0.040 (-11.11%)
ENTBF : 0.0340 (-10.53%)
Ehave, Inc. Announces Psychedelics Precision Medicine Platform For Clinical Research

AI-driven discovery platform enables new way to find novel pathways, as well as progress towards identifying patients who may better respond to drugs in...

OTC.VN : 0.500 (unch)
EHVVF : 0.0064 (+6.67%)
ENBI.CN : 0.040 (-11.11%)
ENTBF : 0.0340 (-10.53%)
Stocks in play: Entheon Biomedical Corp.

Announced that its expanded psychedelics genetic testing panel, developed by its wholly-owned subsidiary, ...

ENBI.CN : 0.040 (-11.11%)
Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) Featured in Virtual Coverage of Benzinga’s Small Cap Conference

Entheon Biomedical (CSE: ENBI) (OTCQB: ENTBF) is researching and developing psychedelic drugs for the treatment of addiction disorders. With a focus on the psychedelic DMT molecule, Entheon’s upcoming...

ENBI.CN : 0.040 (-11.11%)
ENTBF : 0.0340 (-10.53%)
Microdose Psychedelic Insights Presents the Upcoming DMT Conference, a Deep Dive Into the Dynamic Field of DMT Therapeutics

NEW YORK, Aug. 30, 2021 (GLOBE NEWSWIRE) -- via NetworkNewsWire -- Microdose Psychedelic Insights , a cutting-edge media company focused on promoting content, financial analysis, and engaging events...

ENBI.CN : 0.040 (-11.11%)
ENTBF : 0.0340 (-10.53%)
DMT.VN : 0.165 (+3.13%)
AGN.CN : 4.200 (unch)
AGNPF : 3.0300 (+0.33%)
Canadian Government Agency Removes Barrier for Psilocybin Therapy

Palm Beach, FL – December 16, 2020 – Health Canada, in a recent “breakthrough Exemption” has quietly expanded its list of who can legally possess and consume psilocybin-containing mushrooms...

PULL.CN : 0.020 (unch)
MYCO.CN : 0.400 (-6.98%)
RVVTF : 0.1740 (-8.42%)
RVV.CN : 0.235 (-9.62%)
LKYSF : 0.4800 (-3.63%)
NUMI.VN : 0.580 (+9.43%)
ENTBF : 0.0340 (-10.53%)
ENBI.CN : 0.040 (-11.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Key Turning Points

3rd Resistance Point 0.040
2nd Resistance Point 0.040
1st Resistance Point 0.040
Last Price 0.040
1st Support Level 0.040
2nd Support Level 0.040
3rd Support Level 0.040

See More

52-Week High 0.710
Fibonacci 61.8% 0.454
Fibonacci 50% 0.375
Fibonacci 38.2% 0.296
Last Price 0.040
52-Week Low 0.040

See More

Business Summary

Entheon Biomedical Corp is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (DMT Products) for the purposes of treating addiction and substance use disorders. Entheon...

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar